Mini Review
Published on 16 Jul 2020
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00634
- 18,831 views
- 75 citations
Type at least 3 characters
1,082 articles
Articles
Original Research
Published on 16 Jul 2020
A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00608
- 4,741 views
- 35 citations
Mini Review
Published on 15 Jul 2020
Can Operant Conditioning of EMG-Evoked Responses Help to Target Corticospinal Plasticity for Improving Motor Function in People With Multiple Sclerosis?
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00552
- 3,803 views
- 2 citations
Brief Research Report
Published on 15 Jul 2020
Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00606
- 4,643 views
- 26 citations
Case Report
Published on 14 Jul 2020
A Case With IgG4-Related Spinal Pachymeningitis Causing Spinal Cord Compression
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00500
- 4,048 views
- 3 citations
Clinical Trial
Published on 14 Jul 2020
The Role of Cerebral Hypoperfusion in Multiple Sclerosis (ROCHIMS) Trial in Multiple Sclerosis: Insights From Negative Results
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00674
- 2,625 views
- 5 citations
Review
Published on 07 Jul 2020
Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00638
- 5,105 views
- 11 citations
Perspective
Published on 07 Jul 2020
Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00566
- 4,507 views
- 19 citations
Original Research
Published on 07 Jul 2020
Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00642
- 3,945 views
- 14 citations
Review
Published on 03 Jul 2020
SeXX Matters in Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00616
- 3,671,564 views
- 40 citations
Mini Review
Published on 03 Jul 2020
The NMDA Receptor Antibody Paradox: A Possible Approach to Developing Immunotherapies Targeting the NMDA Receptor
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00635
- 10,282 views
- 10 citations
Brief Research Report
Published on 30 Jun 2020
Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00536
- 9,147 views
- 18 citations
Brief Research Report
Published on 25 Jun 2020
Distinct Functional Connectivity Signatures of Impaired Social Cognition in Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00507
- 4,323 views
- 26 citations
Original Research
Published on 17 Jun 2020
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00542
- 3,854 views
- 47 citations
Review
Published on 17 Jun 2020
Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00450
- 8,613 views
- 31 citations
Brief Research Report
Published on 17 Jun 2020
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2020.00489
- 3,932 views
- 13 citations